Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers

Neurology

Volumn 86, Issue 11, 2016, Pages 994-999

  Fraser, Kyle B ^a   Moehle, Mark S ^a   Alcalay, Roy N ^b   West, Andrew B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; BIOLOGICAL MARKER; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MODIFICATION; ENZYME PHOSPHORYLATION; EXOSOME; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MALE; MONTREAL COGNITIVE ASSESSMENT; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UNIFIED PARKINSON DISEASE RATING SCALE; URINALYSIS; ANIMAL; CROSS-SECTIONAL STUDY; GENETICS; HEK293 CELL LINE; MIDDLE AGED; MOUSE; PARKINSONIAN DISORDERS; PHOSPHORYLATION; PHYSIOLOGY; PILOT STUDY; URINE;

AGED; ANIMALS; BIOMARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; HEK293 CELLS; HETEROZYGOTE; HUMANS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MALE; MICE; MIDDLE AGED; PARKINSONIAN DISORDERS; PHENOTYPE; PHOSPHORYLATION; PILOT PROJECTS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84961266899     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002436     Document Type: Article

References (17)

1. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. The Lancet 2005;365:415-416
2. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600
3. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607
4. Healy DG, Falchi M, O'sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590
5. Alcalay RN, Mirelman A, Saunders-Pullman R, et al. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord 2013; 28:1966-1971
6. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425
7. Trinh J, Guella I, Farrer MJ. Disease penetrance of lateonset parkinsonism: a meta-analysis. JAMA Neurol 2014; 71:1535-1539
8. Helmich RC, Thaler A, Van Nuenen BF, et al. Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers. Neurology 2015;84:399-406
9. West AB, Moore DJ, Biskup S, et al. Parkinson's diseaseassociated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005;102: 16842-16847
10. Webber PJ, Smith AD, Sen S, Renfrow MB, Mobley JA, West AB. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol 2011;412:94-110
11. Sheng Z, Zhang S, Bustos D, et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med 2012;4:164ra161
12. Fraser KB, Moehle MS, Daher JP, et al. LRRK2 secretion in exosomes is regulated by 14-3-3. Hum Mol Genet 2013;22:4988-5000
13. Ho DH, Yi S, Seo H, Son I, Seol W. Increased DJ-1 in urine exosome of Korean males with Parkinson's disease. Biomed Res Int 2014;2014:704678
14. West AB, Moore DJ, Choi C, et al. Parkinson's diseaseassociated mutations in LRRK2 link enhanced GTPbinding and kinase activities to neuronal toxicity. Hum Mol Genet 2007;16:223-232
15. Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005;128: 2786-2796
16. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 2010;11:791-797
17. West AB. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord 2015;30:180-189